Larimar Therapeutics Inc [LRMR] stock is trading at $9.29, up 4.15%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The LRMR shares have gain 22.72% over the last week, with a monthly amount glided 32.90%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Larimar Therapeutics Inc [NASDAQ: LRMR] stock has seen the most recent analyst activity on October 16, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $26. Previously, Wedbush started tracking the stock with Outperform rating on October 03, 2024, and set its price target to $22. On October 02, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $15 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $16 on September 04, 2024. Leerink Partners initiated its recommendation with a Outperform and recommended $25 as its price target on April 03, 2024. Citigroup upgraded its rating to Buy for this stock on November 17, 2023, but kept the price target unchanged to $4.50. In a note dated October 19, 2022, Guggenheim initiated an Buy rating and provided a target price of $12 on this stock.
Larimar Therapeutics Inc [LRMR] stock has fluctuated between $2.18 and $13.68 over the past year. Currently, Wall Street analysts expect the stock to reach $20.33 within the next 12 months. Larimar Therapeutics Inc [NASDAQ: LRMR] shares were valued at $9.29 at the most recent close of the market. An investor can expect a potential return of 118.84% based on the average LRMR price forecast.
Analyzing the LRMR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.36 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.93 points at the first support level, and at 8.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.58, and for the 2nd resistance point, it is at 9.86.
Ratios To Look Out For
For context, Larimar Therapeutics Inc’s Current Ratio is 13.10. As well, the Quick Ratio is 13.10, while the Cash Ratio is 2.15.
Transactions by insiders
Recent insider trading involved Hamilton Thomas Edward, Director, that happened on Feb 16 ’24 when 57208.0 shares were purchased. Director, Flynn James E completed a deal on Feb 16 ’24 to buy 4.29 million shares. Meanwhile, Director THOMAS FRANK E bought 2000.0 shares on Feb 14 ’24.
